Staar Surgical Company STAA

$22.47 +0.09 (0.40%)

Valuation

Market cap
1,122,223,000
Revenue TTM
$239,440,000
Net income TTM
$-80,450,000
PE ratio
35.33
Forward PE
57.97
Profit margin
-33.60%
Debt to equity
0.00

Trading

Volume
640,000
Avg volume
1,014,144
Day's range
$22.08 – $22.78
Shares out
50,144,000
Stochastic %K
87%
Beta
1.17
Analysts
Sell
Price target
$28.22

Price

Company profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, h...

Show more

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Industry
Medical Instruments & Supplies
Sector
Healthcare
Phone
626 303 7902
Website
https://www.staar.com
Address
25510 Commercentre Drive, Lake Forest, United States

Latest news

No headlines yet.